CRT 2019: Sviluppo della prima piattaforma per ottimizzare la gestione e il trattamento di pazienti giovani adulti (under-50) affetti da tumore polmonare in Piemonte

Non-small cell lung cancer in young (under-45) patients (ypNSCLC) is an increasing socially relevant phenomenon accounting for about 5.3% of NSCLC. In Piedmont the real incidence is not well assessed. Most of ypNSCLC are diagnosed in advanced stages and are more likely to harbor driver genomic alterations for which there is a growing array of evidence-based targeted therapies.